BioWorld

June 4, 2004

BioMarin Reports Positive Phase III Aryplase Results

BioMarin Pharmaceutical Inc. on Thursday released favorable data from a Phase III trial of Aryplase, an enzyme-replacement therapy for mucopolysaccharidosis-VI patients. (BioWorld Today) Read More

Maxygen Sells Plant Sciences Unit To DuPont For $64M Cash

FDA, CV Therapeutics Nail Down Ranexa Trial Protocol

Panacos, Vitex Merging In $27M Stock Exchange, Plus Milestones

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 18, 2025.

An early stage 85% remissions rate in AML drives Aptevo’s stock surge

BioWorld

An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...

BIO 2025: Makary lays out FDA’s path, launches pilot review program

BioWorld

On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...

3D illustration of a chain of amino acid or biomolecules called protein

Alphadesign: AI creating proteins from scratch

BioWorld Science

The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...